Zovirax Rx-to-OTC switch
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs and Antiviral Drugs Advisory Committees will review data on the Rx-to-OTC switch of Burroughs Wellcome's genital herpes drug Zovirax (acyclovir) at a Jan. 12 joint meeting, the agency said. Formal review of the switch application was postponed in July to allow Burroughs Wellcome to submit data addressing concerns raised at an FDA public hearing in May ("The Tan Sheet" July 4, p. 1)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning